Latest news with #StephenBarker
Business Insider
5 days ago
- Business
- Business Insider
Sumitomo Dainippon Pharma Co (DNPUF) Gets a Buy from Jefferies
Jefferies analyst Stephen Barker maintained a Buy rating on Sumitomo Dainippon Pharma Co on August 1 and set a price target of Yen1,600.00. The company's shares closed last Thursday at $7.24. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Barker covers the Healthcare sector, focusing on stocks such as Sumitomo Dainippon Pharma Co, Otsuka Holdings Co, and Eisai Co. According to TipRanks, Barker has an average return of 8.8% and a 51.35% success rate on recommended stocks. In addition to Jefferies, Sumitomo Dainippon Pharma Co also received a Buy from J.P. Morgan's Seiji Wakao in a report issued on July 30. However, on July 31, TR | OpenAI – 4o reiterated a Hold rating on Sumitomo Dainippon Pharma Co (Other OTC: DNPUF). Based on Sumitomo Dainippon Pharma Co's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $105.65 billion and a net profit of $2.42 billion. In comparison, last year the company earned a revenue of $79.53 billion and had a GAAP net loss of $197.26 billion
Business Insider
20-07-2025
- Business
- Business Insider
Jefferies Sticks to Their Buy Rating for Otsuka Holdings Co (OTSKF)
Jefferies analyst Stephen Barker maintained a Buy rating on Otsuka Holdings Co today and set a price target of Yen9,500.00. The company's shares closed last Tuesday at $44.40. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Barker covers the Healthcare sector, focusing on stocks such as Sumitomo Dainippon Pharma Co, Otsuka Holdings Co, and Astellas Pharma. According to TipRanks, Barker has an average return of 6.3% and a 48.57% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Otsuka Holdings Co with a $60.62 average price target, implying a 36.53% upside from current levels. In a report released on July 15, J.P. Morgan also maintained a Buy rating on the stock with a Yen11,000.00 price target.
Business Insider
09-07-2025
- Business
- Business Insider
Jefferies Reaffirms Their Buy Rating on Sumitomo Dainippon Pharma Co (DNPUF)
In a report released today, Stephen Barker from Jefferies maintained a Buy rating on Sumitomo Dainippon Pharma Co, with a price target of Yen1,300.00. The company's shares closed yesterday at $6.34. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Barker is a 3-star analyst with an average return of 2.9% and a 47.06% success rate. Barker covers the Healthcare sector, focusing on stocks such as Sumitomo Dainippon Pharma Co, Astellas Pharma, and Asahi Intecc Co. The word on The Street in general, suggests a Hold analyst consensus rating for Sumitomo Dainippon Pharma Co with a $5.93 average price target.
NZ Herald
16-06-2025
- NZ Herald
What it's like flying Jetstar from Hamilton to Sydney
The Jetstar flight upon arrival at Hamilton Airport. Photo / Stephen Barker, Barker Photography Jetstar's first flight from Hamilton to Sydney lifted off on Monday. Danielle Zollickhofer checked it out. Visas and requirements: New Zealanders only need their passport to board the plane, no visa is required. However, I was travelling on a German passport, so I had to apply for a visitor visa
Business Insider
01-06-2025
- Business
- Business Insider
Morgan Stanley Sticks to Their Hold Rating for Eisai Co (ESALF)
In a report released on May 29, Shinichiro Muraoka from Morgan Stanley maintained a Hold rating on Eisai Co (ESALF – Research Report), with a price target of Yen4,100.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Muraoka covers the Healthcare sector, focusing on stocks such as Astellas Pharma, Daiichi Sankyo Company, and Eisai Co. According to TipRanks, Muraoka has an average return of -3.9% and a 33.33% success rate on recommended stocks. In addition to Morgan Stanley, Eisai Co also received a Hold from Jefferies's Stephen Barker in a report issued yesterday. However, on May 15, Bernstein maintained a Buy rating on Eisai Co (Other OTC: ESALF).
